ArticleVascular specialist international2026
The Excluded Saphenous Vein Technique for Great Saphenous Vein Reflux: Five-Year Outcomes from an Institutional Experience.
Article in Vascular specialist international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to assess the long-term effectiveness of the Excluded Saphenous Vein Technique (ESVT) in patients with varicose veins (VVs) associated with great saphenous vein (GSV) incompetence. Materials and Methods: Patients who underwent ESVT for primary GSV incompetence associated with VVs between January 2017 and December 2019 were included in this retrospective analysis of a prospectively maintained institutional database. Eligible patients had Clinical, Etiologic, Anatomic, and Pathophysiologic class C2 disease. ESVT consists of selective crossectomy, distal ligation of the GSV at the level of the incompetent thigh tributary, catheter-assisted foam sclerotherapy of the excluded GSV segment, and concomitant phlebectomy of non-saphenous varicosities. The primary endpoint was cumulative GSV recanalization during 5-year follow-up. Secondary endpoints included perioperative complications and VV recurrence. Results: Among 312 patients treated during the study period, 268 met the eligibility criteria, and 239 patients with 349 treated limbs had complete 5-year follow-up. The median GSV diameter was 11 mm (interquartile range, 8-14 mm). All procedures were performed in a day-surgery setting. Transient skin dyschromia occurred in 6.3% of patients, persistent dyschromia in 2.1%, and superficial vein thrombosis in 2.1%; all were managed conservatively. No clinically detected deep vein thrombosis or symptomatic pulmonary embolism occurred. During 5-year follow-up, GSV recanalization occurred in 22/349 treated limbs (6.3%), involving 22/239 patients (9.2%). Recurrent VVs were observed in 59 patients (24.7%). Conclusion: ESVT appears to be a safe and effective treatment option for selected patients with primary GSV reflux and VVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.